TROP-2-targeted antibody-drug conjugate

DRUG CLASS:

TROP-2-targeted antibody-drug conjugate

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	DS-1062a Sensitive: B - Late Trials DS-1062a Sensitive : B	DS-1062a Sensitive: B - Late Trials DS-1062a Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	DS-1062a Sensitive: B - Late Trials DS-1062a Sensitive : B	DS-1062a Sensitive: B - Late Trials DS-1062a Sensitive : B
TROP2 expression	Non Small Cell Lung Cancer	TROP2 expression	Non Small Cell Lung Cancer	DS-1062a Sensitive: C2 – Inclusion Criteria DS-1062a Sensitive : C2	DS-1062a Sensitive: C2 – Inclusion Criteria DS-1062a Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	DS-1062a Sensitive: C2 – Inclusion Criteria DS-1062a Sensitive : C2	DS-1062a Sensitive: C2 – Inclusion Criteria DS-1062a Sensitive : C2
TROP2 overexpression	Non Small Cell Lung Cancer	TROP2 overexpression	Non Small Cell Lung Cancer	DS-1062a Sensitive: C3 – Early Trials DS-1062a Sensitive : C3	DS-1062a Sensitive: C3 – Early Trials DS-1062a Sensitive : C3
BRCA1 mutation	Endometrial Cancer	BRCA1 mutation	Endometrial Cancer	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3
TROP2 overexpression	Triple Negative Breast Cancer	TROP2 overexpression	Triple Negative Breast Cancer	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials pembrolizumab + DS-1062a Sensitive : C3
TP53 mutation + MDM2 mutation	Urothelial Cancer	TP53 mutation + MDM2 mutation	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials sacituzumab govitecan-hziy Sensitive : C3	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials sacituzumab govitecan-hziy Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ESG401 Sensitive: C3 – Early Trials ESG401 Sensitive : C3	ESG401 Sensitive: C3 – Early Trials ESG401 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3	MK-2870 Sensitive: C3 – Early Trials MK-2870 Sensitive : C3
MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4
TROP2 overexpression	Triple Negative Breast Cancer	TROP2 overexpression	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 overexpression	Triple Negative Breast Cancer	TROP2 overexpression	Triple Negative Breast Cancer	BAT8003 Sensitive: D – Preclinical BAT8003 Sensitive : D	BAT8003 Sensitive: D – Preclinical BAT8003 Sensitive : D
TROP2 expression	Cervical Cancer	TROP2 expression	Cervical Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 overexpression	Endometrial Cancer	TROP2 overexpression	Endometrial Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 expression	Breast Cancer	TROP2 expression	Breast Cancer	DS-1062a Sensitive: D – Preclinical DS-1062a Sensitive : D	DS-1062a Sensitive: D – Preclinical DS-1062a Sensitive : D
TROP2 positive	Breast Cancer	TROP2 positive	Breast Cancer	BAT8008 Sensitive: D – Preclinical BAT8008 Sensitive : D	BAT8008 Sensitive: D – Preclinical BAT8008 Sensitive : D
TROP2 positive	Triple Negative Breast Cancer	TROP2 positive	Triple Negative Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
RAB5A expression	HER2 Positive Breast Cancer	RAB5A expression	HER2 Positive Breast Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 expression	Colon Cancer	TROP2 expression	Colon Cancer	DS-1062a Sensitive: D – Preclinical DS-1062a Sensitive : D	DS-1062a Sensitive: D – Preclinical DS-1062a Sensitive : D

TROP-2-targeted antibody-drug conjugate

TROP-2-targeted antibody-drug conjugate

Associations(51)

Associations
(51)